{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:07:51Z","timestamp":1787166471434,"version":"build-2736575974"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T00:00:00Z","timestamp":1579564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2314-B-038-073"],"award-info":[{"award-number":["MOST 108-2314-B-038-073"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s10067-019-04893-8","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:05:01Z","timestamp":1579637101000},"page":"1633-1648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"39","author":[{"given":"Yu-Jiun","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyng-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hsien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen-Te","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shy-Shin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,21]]},"reference":[{"issue":"1","key":"4893_CR1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P et al (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76(1):29\u201342","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"4893_CR2","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D et al (2012) American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 64(10):1431\u20131446","journal-title":"Arthritis Care Res"},{"issue":"7","key":"4893_CR3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald T, Nuki G, Pywell A, Zhang W, Roddy E, British Society for Rheumatology Standards, Audit and Guidelines Working Group (2017) The British Society for Rheumatology guideline for the management of gout. Rheumatology 56(7):e1\u2013e20","journal-title":"Rheumatology"},{"issue":"4","key":"4893_CR4","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/1756-185X.13266","volume":"21","author":"KH Yu","year":"2018","unstructured":"Yu KH, Chen DY, Chen JH, Chen SY, Chen SM, Cheng TT et al (2018) Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. Int J Rheum Dis. 21(4):772\u2013787","journal-title":"Int J Rheum Dis."},{"issue":"1","key":"4893_CR5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/M16-0461","volume":"166","author":"PG Shekelle","year":"2017","unstructured":"Shekelle PG, Newberry SJ, FitzGerald J, Motala A, O'Hanlon CE, Tariq A, Okunogbe A, Han D, Shanman R (2017) Management of gout: a systematic review in support of an American college of physicians clinical practice guideline. Ann Intern Med 166(1):37\u201351","journal-title":"Ann Intern Med"},{"issue":"1","key":"4893_CR6","doi-asserted-by":"crossref","first-page":"050","DOI":"10.30574\/gscbps.2018.5.1.0077","volume":"5","author":"K Ashiq","year":"2018","unstructured":"Ashiq K et al (2018) A systematic review on the prevalence, pathophysiology, diagnosis, management and treatment of gout (2007-2018). GSC Biol Pharm Sci 5(1):050\u2013055","journal-title":"GSC Biol Pharm Sci"},{"issue":"1","key":"4893_CR7","first-page":"88","volume":"6","author":"S Ahmed","year":"2018","unstructured":"Ahmed S et al (2018) Pathophysiology, clinical consequences, epidemiology and treatment of hyperurecemic gout. RADS J Pharm Pharm Sci 6(1):88\u201393","journal-title":"RADS J Pharm Pharm Sci"},{"issue":"2","key":"4893_CR8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2018.02.009","volume":"48","author":"L Stamp","year":"2018","unstructured":"Stamp L, Morillon MB, Taylor WJ, Dalbeth N, Singh JA, Lassere M et al (2018) Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis. Semin Arthritis Rheum. 48(2):293\u2013301","journal-title":"Semin Arthritis Rheum."},{"issue":"1","key":"4893_CR9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-018-1143-7","volume":"20","author":"Q Luo","year":"2019","unstructured":"Luo Q, Xia X, Li B, Lin Z, Yu X, Huang F (2019) Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrol. 20(1):18","journal-title":"BMC Nephrol."},{"key":"4893_CR10","first-page":"6905720","volume":"2018","author":"J Liu","year":"2018","unstructured":"Liu J, Tao L, Zhao Z, Mu Y, Zou D, Zhang J et al (2018) Two-Year Changes in Hyperuricemia and Risk of Diabetes: A Five-Year Prospective Cohort Study. J Diabetes Res. 2018:6905720","journal-title":"J Diabetes Res."},{"issue":"1","key":"4893_CR11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12944-017-0531-5","volume":"16","author":"X Zheng","year":"2017","unstructured":"Zheng X, Gong L, Luo R, Chen H, Peng B, Ren W et al (2017) Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults. Lipids Health Dis. 16(1):202","journal-title":"Lipids Health Dis."},{"issue":"7","key":"4893_CR12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s10157-019-01705-w","volume":"23","author":"F Zhou","year":"2019","unstructured":"Zhou F et al (2019) Association of serum uric acid levels with the incident of kidney disease and rapid eGFR decline in Chinese individuals with eGFR\u2009>\u200960 mL\/min\/1.73 m2 and negative proteinuria. Clin Exp Nephrol 23(7):871\u2013879","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"4893_CR13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1080\/13548506.2017.1378819","volume":"23","author":"T Fu","year":"2018","unstructured":"Fu T et al (2018) Depression and anxiety correlate with disease-related characteristics and quality of life in Chinese patients with gout: a case-control study. Psychol Health Med 23(4):400\u2013410","journal-title":"Psychol Health Med"},{"issue":"5","key":"4893_CR14","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/03009742.2017.1405461","volume":"47","author":"AA Kiadaliri","year":"2018","unstructured":"Kiadaliri AA, Englund M, Uhlig T (2018) Burden of gout in the Nordic region, 1990\u20132015: findings from the Global Burden of Disease Study 2015. Scand J Rheumatol 47(5):410\u2013417","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"4893_CR15","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1038\/s41598-018-22570-9","volume":"8","author":"P Song","year":"2018","unstructured":"Song P, Wang H, Xia W, Chang X, Wang M, An L (2018) Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. Sci Rep. 8(1):4314","journal-title":"Sci Rep."},{"issue":"4","key":"4893_CR16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M (2015) Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 74(4):661\u2013667","journal-title":"Ann Rheum Dis."},{"issue":"3","key":"4893_CR17","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s10067-014-2823-8","volume":"35","author":"B McGowan","year":"2016","unstructured":"McGowan B, Bennett K, Silke C, Whelan B (2016) Adherence and persistence to urate-lowering therapies in the Irish setting. Clin Rheumatol. 35(3):715\u2013721","journal-title":"Clin Rheumatol."},{"issue":"8","key":"4893_CR18","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s10067-018-4127-x","volume":"37","author":"CA Janssen","year":"2018","unstructured":"Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar M (2018) A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands. Clin Rheumatol. 37(8):2291\u20132296","journal-title":"Clin Rheumatol."},{"key":"4893_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","volume":"431","author":"H Yamanaka","year":"1998","unstructured":"Yamanaka H, Togashi R, Hakoda M, Terai C, Kashiwazaki S, Dan T, Kamatani N (1998) Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 431:13\u201318","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"4893_CR20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11606-017-4233-5","volume":"33","author":"V Beslon","year":"2018","unstructured":"Beslon V, Moreau P, Maruani A, Maisonneuve H, Giraudeau B, Fournier JP (2018) Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review. J Gen Intern Med. 33(3):358\u2013366","journal-title":"J Gen Intern Med."},{"issue":"3","key":"4893_CR21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","volume":"132","author":"TR Mikuls","year":"2019","unstructured":"Mikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, Coburn BW, Redden DT, Saag KG, Foster PJ, Chen L, Curtis JR (2019) Adherence and outcomes with urate-lowering therapy: a site-randomized trial. Am J Med 132(3):354\u2013361","journal-title":"Am J Med"},{"issue":"1","key":"4893_CR22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bcp.13427","volume":"84","author":"D Hill-McManus","year":"2018","unstructured":"Hill-McManus D, Soto E, Marshall S, Lane S, Hughes D (2018) Impact of non-adherence on the safety and efficacy of uric acid-lowering therapies in the treatment of gout. Br J Clin Pharmacol. 84(1):142\u2013152","journal-title":"Br J Clin Pharmacol."},{"issue":"10","key":"4893_CR23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40273-015-0288-5","volume":"33","author":"G Shields","year":"2015","unstructured":"Shields G, Beard SM (2015) A systematic review of the economic and humanistic burden of gout. PharmacoEconomics 33(10):1029\u20131047","journal-title":"PharmacoEconomics"},{"issue":"10","key":"4893_CR24","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Choi HK, Pandya BJ (2011) Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 63(10):3136\u20133141","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4893_CR25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","volume":"47","author":"LEJM Scheepers","year":"2018","unstructured":"Scheepers LEJM et al (2018 Apr) (2018) Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum. 47(5):689\u2013702","journal-title":"Semin Arthritis Rheum."},{"key":"4893_CR26","doi-asserted-by":"crossref","first-page":"33082","DOI":"10.1038\/srep33082","volume":"6","author":"S Li","year":"2016","unstructured":"Li S, Yang H, Guo Y, Wei F, Yang X, Li D et al (2016) Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Sci Rep. 6:33082","journal-title":"Sci Rep."},{"issue":"11","key":"4893_CR27","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/phar.2183","volume":"38","author":"J-Y Wu","year":"2018","unstructured":"Wu J-Y, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW (2018) Efficacy and safety of lesinurad in patients with hyperuricemia associated with gout: a systematic review and meta-analysis of randomized controlled trials. Pharmacotherapy 38(11):1106\u20131119","journal-title":"Pharmacotherapy"},{"issue":"4","key":"4893_CR28","doi-asserted-by":"publisher","first-page":"CD008652","DOI":"10.1002\/14651858.CD008652.pub3","volume":"4","author":"PH Franca Gois","year":"2017","unstructured":"Franca Gois PH, de Moraes Souza ER (2017) Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev 4(4):CD008652. Published 2017 Apr 13. https:\/\/doi.org\/10.1002\/14651858.CD008652.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"23","key":"4893_CR29","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450\u20132461","journal-title":"N Engl J Med"},{"issue":"2","key":"4893_CR30","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","volume":"12","author":"MA Becker","year":"2010","unstructured":"Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 12(2):R63","journal-title":"Arthritis Res Ther."},{"issue":"20","key":"4893_CR31","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","volume":"131","author":"MM Givertz","year":"2015","unstructured":"Givertz MM, Anstrom KJ, Redfield MM, Deswal A, Haddad H, Butler J et al (2015) Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation. 131(20):1763\u20131771","journal-title":"Circulation."},{"issue":"11","key":"4893_CR32","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.2215\/CJN.01760213","volume":"8","author":"DS Goldfarb","year":"2013","unstructured":"Goldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L (2013) Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol. 8(11):1960\u20131967","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"4893_CR33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/jcpt.12391","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R (2016) Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J Clin Pharm Ther. 41(3):290\u2013297","journal-title":"J Clin Pharm Ther."},{"issue":"3","key":"4893_CR34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10067-016-3474-8","volume":"36","author":"T Hosoya","year":"2017","unstructured":"Hosoya T, Sasaki T, Ohashi T (2017) Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clin Rheumatol. 36(3):649\u2013656","journal-title":"Clin Rheumatol."},{"issue":"6","key":"4893_CR35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/1756-185X.12266","volume":"17","author":"X Huang","year":"2014","unstructured":"Huang X, Du H, Gu J, Zhao D, Jiang L, Li X et al (2014) An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis. 17(6):679\u2013686","journal-title":"Int J Rheum Dis."},{"issue":"4 Suppl 2","key":"4893_CR36","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","volume":"17","author":"N Kamatani","year":"2011","unstructured":"Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y (2011) An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol 17(4 Suppl 2):S13\u2013S18","journal-title":"J Clin Rheumatol"},{"issue":"4 Suppl 2","key":"4893_CR37","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/RHU.0b013e31821d352f","volume":"17","author":"K Naoyuki","year":"2011","unstructured":"Naoyuki K et al (2011) An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study. J Clin Rheumatol 17(4 Suppl 2):S44\u2013S49","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"4893_CR38","first-page":"52","volume":"2","author":"B Kumar","year":"2013","unstructured":"Kumar B, Agarwal PK (2013) Comparative evaluation of efficacy and safety profile of febuxostat with allopurinol in patients with hyperuricemia and gout. Int J Pharm Med Biol Sci 2(4):52\u201356","journal-title":"Int J Pharm Med Biol Sci"},{"key":"4893_CR39","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ijcme.2015.07.001","volume":"8","author":"A Nakagomi","year":"2015","unstructured":"Nakagomi A et al (2015) Effects of febuxostat and allopurinol on the inflammation and cardiac function in chronic heart failure patients with hyperuricemia. IJC Metab Endocrine 8:46\u201355","journal-title":"IJC Metab Endocrine"},{"issue":"2","key":"4893_CR40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","volume":"5","author":"F Perez-Ruiz","year":"1999","unstructured":"Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, Herrero-Beites A, Ruiz-Lucea E, Garcia-Erauskin G et al (1999) Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol. 5(2):49\u201355","journal-title":"J Clin Rheumatol."},{"issue":"8","key":"4893_CR41","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","volume":"68","author":"J Poiley","year":"2016","unstructured":"Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA et al (2016) A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol. 68(8):2027\u20132034","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"4893_CR42","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA et al (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout. Ann Rheum Dis. 68(6):892\u2013897","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"4893_CR43","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59(11):1540\u20131548","journal-title":"Arthritis Rheum."},{"issue":"8","key":"4893_CR44","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1253\/circj.CJ-13-0082","volume":"77","author":"A Sezai","year":"2013","unstructured":"Sezai A, Soma M (2013) Nakata K-i, Hata M, Yoshitake I, Wakui S, et al. Comparison of Febuxostat and Allopurinol for Hyperuricemia in Cardiac Surgery Patients (NU-FLASH Trial). Circulation Journal. 77(8):2043\u20132049","journal-title":"Circulation Journal."},{"issue":"13","key":"4893_CR45","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB et al (2018) Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 378(13):1200\u20131210","journal-title":"N Engl J Med"},{"issue":"6","key":"4893_CR46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","volume":"18","author":"S Xu","year":"2015","unstructured":"Xu S, Liu X, Ming J, Chen S, Wang Y, Liu X et al (2015) A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis. 18(6):669\u2013678","journal-title":"Int J Rheum Dis."},{"issue":"4","key":"4893_CR47","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/03009742.2015.1099729","volume":"45","author":"KH Yu","year":"2016","unstructured":"Yu KH, Lai JH, Hsu PN, Chen DY, Chen CJ, Lin HY (2016) Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study. Scand J Rheumatol 45(4):304\u2013311","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"4893_CR48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","volume":"20","author":"L Gunawardhana","year":"2018","unstructured":"Gunawardhana L, Becker MA, Whelton A, Hunt B, Castillo M, Saag K (2018) Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 20(1):99","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"4893_CR49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/art.40685","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag KG, Becker MA, Whelton A, Hunt B, Castillo M, Kisfalvi K, Gunawardhana L (2019) Efficacy and safety of febuxostat extended and immediate release in patients with gout and renal impairment: a phase III placebo-controlled study. Arthritis Rheumatol 71(1):143\u2013153","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"4893_CR50","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald P, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum 52(3):916\u2013923","journal-title":"Arthritis Rheum"},{"issue":"4 Suppl 2","key":"4893_CR51","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/RHU.0b013e31821d36de","volume":"17","author":"K Naoyuki","year":"2011","unstructured":"Naoyuki K et al (2011) Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study. J Clin Rheumatol 17(4 Suppl 2):S19\u2013S26","journal-title":"J Clin Rheumatol"},{"issue":"4 Suppl 2","key":"4893_CR52","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/RHU.0b013e31821d351d","volume":"17","author":"K Naoyuki","year":"2011","unstructured":"Naoyuki K et al (2011) Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in Japan: late phase 2 clinical study. J Clin Rheumatol 17(4 Suppl 2):S35\u2013S43","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"4893_CR53","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y, FEATHER Study Investigators (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72(6):798\u2013810","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"4893_CR54","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/art.40233","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald P, Thienel U, Gunawardhana L (2017) Effects of febuxostat in early gout: a randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 69(12):2386\u20132395","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"4893_CR55","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/art.39654","volume":"68","author":"KG Saag","year":"2016","unstructured":"Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L (2016) Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol 68(8):2035\u20132043","journal-title":"Arthritis Rheumatol"},{"key":"4893_CR56","first-page":"51","volume":"8","author":"P Usharani","year":"2016","unstructured":"Usharani P, Nutalapati C, Pokuri VK, Kumar CU, Taduri G (2016) A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia. Clin Pharmacol Adv Appl 8:51\u201359","journal-title":"Clin Pharmacol Adv Appl"},{"issue":"6","key":"4893_CR57","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10157-014-0935-8","volume":"18","author":"T Hosoya","year":"2014","unstructured":"Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, Yamamoto T, Hara S (2014) Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 18(6):876\u2013884","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"4893_CR58","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/jcpt.12392","volume":"41","author":"T Hosoya","year":"2016","unstructured":"Hosoya T, Sasaki T, Hashimoto H, Sakamoto R, Ohashi T (2016) Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study. J Clin Pharm Ther 41(3):298\u2013305","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"4893_CR59","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","volume":"22","author":"T Wada","year":"2018","unstructured":"Wada T, Hosoya T, Honda D, Sakamoto R, Narita K, Sasaki T, Okui D, Kimura K (2018) Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clin Exp Nephrol 22(4):860\u2013870","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"4893_CR60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, van Roon E, Jansen TL, Delsing J, Griep EN, Hoekstra M, van de Laar M, Brouwers JR (2009) Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68(1):51\u201356","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4893_CR61","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK et al (2017) Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (United Kingdom) 56(12):2170\u20132178","journal-title":"Rheumatology (United Kingdom)"},{"issue":"9","key":"4893_CR62","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1002\/art.23810","volume":"58","author":"JS Sundy","year":"2008","unstructured":"Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip RW 2nd, Maroli AN, Horowitz Z, Pegloticase Phase 2 Study Investigators (2008) Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum 58(9):2882\u20132891","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4893_CR63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","volume":"306","author":"JS Sundy","year":"2011","unstructured":"Sundy JS et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306(7):711\u2013720","journal-title":"JAMA"},{"issue":"5","key":"4893_CR64","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A (2017) Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis 76(5):811\u2013820","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4893_CR65","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","volume":"75","author":"F Perez-Ruiz","year":"2016","unstructured":"Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C, RDEA594-203 Study Group (2016) Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. Ann Rheum Dis 75(6):1074\u20131080","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4893_CR66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","volume":"69","author":"KG Saag","year":"2017","unstructured":"Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA (2017) Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study). Arthritis Rheumatol 69(1):203\u2013212","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"4893_CR67","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N et al (2017) Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol 69(9):1903\u20131913","journal-title":"Arthritis Rheumatol"},{"key":"4893_CR68","unstructured":"Deeks JJ, Higgins JPT, Altman DG (2011) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, ed. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration"},{"issue":"11","key":"4893_CR69","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40266-014-0214-0","volume":"31","author":"LK Stamp","year":"2014","unstructured":"Stamp LK, Chapman PT (2014) Urate-lowering therapy: current options and future prospects for elderly patients with gout. Drugs Aging 31(11):777\u2013786","journal-title":"Drugs Aging"},{"issue":"1","key":"4893_CR70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-018-1596-x","volume":"20","author":"P Drivelegka","year":"2018","unstructured":"Drivelegka P, Sigurdardottir V, Svard A, Jacobsson LTH, Dehlin M (2018) Comorbidity in gout at the time of first diagnosis: sex differences that may have implications for dosing of urate lowering therapy. Arthritis Res Ther. 20(1):108","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"4893_CR71","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12891-017-1465-9","volume":"18","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG et al (2017) Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 18(1):108","journal-title":"BMC Musculoskelet Disord."},{"issue":"9","key":"4893_CR72","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s10067-018-4243-7","volume":"37","author":"JA Singh","year":"2018","unstructured":"Singh JA (2018) Goals of gout treatment: a patient perspective. Clin Rheumatol 37(9):2557\u20132566","journal-title":"Clin Rheumatol"},{"key":"4893_CR73","first-page":"h4848","volume":"351","author":"TM Ko","year":"2015","unstructured":"Ko TM, Tsai CY, Chen SY, Chen KS, Yu KH, Chu CS et al (2015) Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. BMJ. 351:h4848","journal-title":"BMJ."},{"issue":"10","key":"4893_CR74","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","volume":"36","author":"SN Ramasamy","year":"2013","unstructured":"Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, Graham GG, Williams KM, Day RO (2013) Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012. Drug Saf 36(10):953\u2013980","journal-title":"Drug Saf"},{"issue":"3","key":"4893_CR75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-018-0722-8","volume":"20","author":"Z Latif","year":"2018","unstructured":"Latif Z, Abhishek A (2018) Are doctors the best people to manage gout? Is there a role for nurses and pharmacists? Curr Rheumatol Rep 20(3):14","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"4893_CR76","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH et al (2008) Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 67(5):609\u2013613","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"4893_CR77","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","volume":"71","author":"M Doherty","year":"2012","unstructured":"Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71(11):1765\u20131770","journal-title":"Ann Rheum Dis"},{"key":"4893_CR78","doi-asserted-by":"crossref","unstructured":"Yin R et al (2017) The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study. Rheumatol Int 1187\u20131194","DOI":"10.1007\/s00296-017-3746-x"},{"issue":"10","key":"4893_CR79","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA De Vera","year":"2014","unstructured":"De Vera MA et al (2014) Medication adherence in gout: a systematic review. Arthritis Care Res 66(10):1551\u20131559","journal-title":"Arthritis Care Res"},{"key":"4893_CR80","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1471-2296-14-170","volume":"14","author":"E Cottrell","year":"2013","unstructured":"Cottrell E et al (2013) Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice. BMC Fam Pract 14:170","journal-title":"BMC Fam Pract"},{"issue":"8","key":"4893_CR81","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s10067-016-3212-2","volume":"35","author":"B Spaetgens","year":"2016","unstructured":"Spaetgens B et al (2016) Knowledge, illness perceptions and stated clinical practice behaviour in management of gout: a mixed methods study in general practice. Clin Rheumatol 35(8):2053\u20132061","journal-title":"Clin Rheumatol"},{"issue":"6","key":"4893_CR82","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/acr.23347","volume":"70","author":"A Latourte","year":"2018","unstructured":"Latourte A, Bardin T, Clerson P, Ea HK, Flipo RM, Richette P (2018) Dyslipidemia, alcohol consumption, and obesity as main factors associated with poor control of urate levels in patients receiving urate-lowering therapy. Arthritis Care Res 70(6):918\u2013924","journal-title":"Arthritis Care Res"},{"issue":"19","key":"4893_CR83","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1001\/jama.295.19.2270","volume":"295","author":"PM Ridker","year":"2006","unstructured":"Ridker PM, Torres J (2006) Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. J Am Med Assoc 295(19):2270\u20132274","journal-title":"J Am Med Assoc"},{"issue":"9296","key":"4893_CR84","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(01)06891-X","volume":"358","author":"JSG Montaner","year":"2001","unstructured":"Montaner JSG, O'Shaughnessy MV, Schechter MT (2001) Industry-sponsored clinical research: a double-edged sword. Lancet 358(9296):1893\u20131895","journal-title":"Lancet"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04893-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T19:54:03Z","timestamp":1611086043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04893-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,21]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["4893"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04893-8","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,21]]},"assertion":[{"value":"29 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}